ArticleAmerican journal of cancer research2026
Serum amyloid P component suppresses melanoma growth and metastasis by inhibiting CCL1 secretion from macrophages.
Article in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of melanoma, which is among the most common skin cancers, has significantly increased at an alarming rate over the past decade. Serum amyloid P component (SAP), a member of the pentraxin (PTX) family, is a major acute-phase protein in mice. The effects of SAP on melanoma and the mechanisms underlying these effects remain unclear. In the current study, we established xenograft and metastatic melanoma models in SAP-overexpressing (SAP-Tg) mice to determine the effect of SAP on the progression of melanoma. Compared with wild-type (WT) mice, SAP-Tg mice developed tumors with smaller volumes and fewer metastatic foci, and the degree of cell proliferation within the transplanted tumors was significantly decreased by SAP. Further study indicated that SAP inhibited melanoma growth and metastasis by suppressing CC-chemokine 1 (CCL1) secretion from activated macrophages, while CCL1 promoted the migration and invasion of B16F10 melanoma cells. Furthermore, SAP-induced CCL1 downregulation suppressed Ras/p-ERK pathway activation. These findings indicate a new effect of SAP mediated via a novel mechanism and provide direct evidence that SAP may have therapeutic value for melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.